The 49Th Annual Meeting of the Japanese Society for Immunology

Total Page：16

File Type：pdf, Size：1020Kb

http://icongroup.co.jp/49immunology/ The 49th Annual Meeting of the Japanese Society for Immunology December 8, 2020－Online Meeting P r e s i d e n t： Hiroshi Kiyono, President and Chairman of Board, JSI COVID-19 and Immunity Keynote Remarks Registration Anthony S. Fauci, Director of NIAID, U.S.A. http://icongroup.co.jp/49immunology/ November 2 (Noon - JST) Symposium Early －November 30 (Noon - JST) Vaccine and Immunity * Credit card or Bank transfer December 1 (Noon - JST) Akiko Iwasaki, Yale University, U.S.A. Late －December 25 (Noon - JST) Alessandro Sette, La Jolla Institute for Immunology, U.S.A. * Credit card only George Fu Gao, China CDC, China Regular Member: 1,000JPY, Student Member: Free Hironori Nakagami, Osaka University, Japan Non-member: 2,000JPY, Student Non-member: 500JPY Ken J Ishii, The University Tokyo, Japan Cytokine Storm and Related Disease ■Steering committee & Program Committee Tadamitsu Kishimoto, Osaka University, Japan Chair: Toshiaki Ohteki, Tokyo Medical and Dental University Josef Penninger, University of British Columbia, Canada Members: Miyuki Azuma, Tokyo Medical and Dental University Yumiko Imai, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Japan Tsuneyasu Kaisho, Wakayama Medical University Takanori Kanai, Keio University, Japan Hiroshi Kawamoto, Kyoto University Hisashi Arase, Osaka University, Japan Noriko Sorimachi, National Center for Global Health and Medicine Kiyoshi Takeda, Osaka University Shohei Hori, The University of Tokyo Review Talk (in Japanese) Koji Yasutomo, Tokushima University Hiroshi Nakajima, Chiba University Masayuki Miyasaka, Osaka University, Japan ■Program Committee Members: Hisashi Arase, Osaka University (in Japanese) Panel Discussion Ken J Ishii, The University Tokyo Yoshimasa Takahashi, NIID Ken J Ishii, The University of Tokyo, Japan Masaaki Murakami, Hokkaido University Yumiko Imai, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Japan Akihiko Yoshimura, Keio University Masayuki Miyasaka, Osaka University, Japan Support: Japan Agency for Medical Research and Development Takanori Kanai, Keio University, Japan Yoshimasa Takahashi, NIID, Japan Congress Secretariat JSI Administration Oﬃce iCON LLC. 1-1-1 Ebisu-minami, Shibuya-ku, Tokyo 150-0022,Japan 2nd Floor, KUMAKI Bldg., 1-4-2 Kandaizumi-cho, Chiyoda-ku, Tokyo, 101-0024, JAPAN TEL: +81 3 6871 9421 E-mail: [email protected] TEL: +81-3-5809-2019 E-mail: [email protected].

Copy Link

Recommended publications

July 2020 Strategies for Emerging Infectious Diseases
THE AMERICAN WWW.CAYMANCHEM.COM ASSOCIATION OF IMMUNOLOGISTS AT ISSUE NEW THE DOWNLOAD Virus Life Cycle Infographic Infographic Cycle Life Virus JULY 2020 Resources for Your Research Your for Resources Informative Articles Informative CAYMAN CURRENTS: CAYMAN IN THIS ISSUE OF THE THE OF ISSUE THIS IN DISEASES INFECTIOUS EMERGING AAI Looks Back: How Honolulu’s Chinatown FOR STRATEGIES "Went Up in Smoke" A history of the first plague outbreak in Hawai’i, page 30 ANTIVIRAL 28 No. Permit CAYMAN CURRENTS PA Gettysburg, PAID 20852 20852 20852 20852 MD MD MD MD Rockville, Rockville, Rockville, Rockville, 650, 650, 650, 650, Suite Suite Suite Suite Pike, Pike, Pike, Pike, Rockville Rockville Rockville Rockville 1451 1451 1451 1451 Postage U.S. Non-Proft Org. Non-Proft IMMUNOLOGISTS IMMUNOLOGISTS IMMUNOLOGISTS IMMUNOLOGISTS OF OF OF OF ASSOCIATION ASSOCIATION ASSOCIATION ASSOCIATION AMERICAN AMERICAN AMERICAN AMERICAN THE THE THE THE 2020 advanced Course in Immunology Now Virtual! I July 26–31, 2020 IN THIS ISSUE Director: Wayne M. Yokoyama, M.D. Washington University School of Medicine in St. Louis x4 Executive Offce The American Association Don’t miss the premier course in immunology for research scientists! of Immunologists x8 Public Affairs This intensive course is directed toward advanced trainees and scientists who wish to expand or update 1451 Rockville Pike, Suite 650 their understanding of the feld. Leading experts will present recent advances in the biology of the Rockville, MD 20852 20 Members in the News immune system and address its role in health and disease. This is not an introductory course; Tel: 301-634-7178 attendees will need to have a frm understanding of the principles of immunology.
[Show full text]
An Interview with Akiko Iwasaki on Her Groundbreaking COVID Projects and Advocacy for Women and Minorities in STEM
Q&A https://doi.org/10.1038/s42003-021-02456-9 OPEN At the frontline of COVID research: an interview with Akiko Iwasaki on her groundbreaking COVID projects and advocacy for women and minorities in STEM Professor Akiko Iwasaki’s research focuses on the mechanisms of immune defense against viruses at mucosal surfaces, which are a major site of entry for infectious agents. Professor Iwasaki received her Ph.D. in Immunology from the University of Toronto and completed her postdoctoral training with the National Institutes of Health before joining Yale’s faculty in 2000. She has received many awards and honors and has been a Howard Hughes Medical Institute Investigator since 2014. She was elected to the 1234567890():,; National Academy of Sciences in 2018, to the National Academy of Medicine in 2019 and to the American Academy of Arts and Sciences in 2021. Professor Iwasaki is also well known for her Twitter advocacy of women and underrepresented minorities in the science and medicine ﬁelds. In addition, Professor Iwasaki co-directs the IMPACT (Implementing Medical and Public Health Actions against Coronavirus in Connecticut) team to generate an extensive biorepository for specimens collected from patients and health care workers, as well as implementing viral testing in both groups. established. Based on this insight, we developed a vaccine strategy called “Prime and Pull”, where we can recruit and establish tissue resident memory T cells at the site of viral encounter. This led to a much more robust protection from genital herpes, and can also be used to treat existing virus infection to prevent recurrence of herpes lesions.
[Show full text]
Hangar Fire Foam Systems: a Problem in the Aviation Industry, with One Event Occuring on Average Every Six Weeks
PUBLICATIONS Vol.49 | No.7 $9.00 JULY 2020 | ainonline.com USAIG Accidental hangar fire foam discharge is a growing Hangar fire foam systems: a problem in the aviation industry, with one event occuring on average every six weeks. The cleanup solution looking for a problem? costs from each can involve numerous insurance by Curt Epstein claims and in some cases lawsuits, pitting aircraft For FBOs, OEMs, and other hangar keepers, senior v-p of insurance provider Global Aero- could be worth more than 10 times the price owners and operators the inadvertent discharge of fire foam sys- space and the author of a white paper on the of the building. against hangar keepers tems is a persistent and growing problem. topic, stated that the average value of foam dis- As aircraft increased in size and fuel and fire system providers. Nearly everyone has seen photos taken in charge claims he has seen has been $1 million. capacity, fire authorities began to worry the aftermath of one of these events—a NATA estimates the overall clean up and air- that sprinklers would not be able to ade- hangar filled with a thick layer of foam that craft damage costs of those events at between quately reach and fight any fuel spill fires can reach 10 feet high, spilling out on to the $64 million and $235 million. that occurred under the ever-widening ramp in some cases. The National Fire Protection Association wings, which at the time had an unpleasant Electric Aircraft In a way, accidental foam discharge is like (NFPA), considered the world’s foremost tendency to leak fuel onto the hangar floor.
[Show full text]
Covid, Sex Discrimination, and Medical Research
COVID, SEX DISCRIMINATION, AND MEDICAL RESEARCH Lori Andrews & Bora Ndregjoni† INTRODUCTION .............................................................. 129 I. THE HISTORY OF MEDICAL RESEARCH ON WOMEN .... 131 II. THE REGULATORY ATTEMPTS TO ADDRESS THE GENDER GAP IN MEDICAL RESEARCH ................................... 135 III. THE DIFFERENTIAL EFFECT OF COVID-19 ON WOMEN AND MEN ............................................................. 143 A. Gendered Analyses of the Incidence of and Effects of COVID-19 ..................................... 145 B. Biological Differences Influencing Reactions to COVID.......................................................... 149 1. Immunological Differences ........................ 149 2. Hormonal Differences ............................... 153 3. Genetic Differences Between Men and Women ................................................................ 154 C. Emerging Studies That Use Research on Women to Guide COVID-19 Treatments.................... 156 IV. POLICY RECOMMENDATIONS .................................. 158 INTRODUCTION When I read that men are nearly twice as likely to die from COVID-19 as women,1 I thought of science fiction books that † Lori Andrews, J.D., is the Director of the Institute for Science, Law and Technology and Distinguished Professor of Law at IIT Chicago-Kent College of Law. Bora Ndregjoni is a third year law student at IIT Chicago-Kent College of Law. The authors thank Monica Pechous, Andrew White, and Kelby Roth for their research in connection with this Article. The
[Show full text]
Multiscale PHATE Exploration of SARS-Cov-2 Data Reveals Multimodal Signatures of Disease
bioRxiv preprint doi: https://doi.org/10.1101/2020.11.15.383661; this version posted November 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Multiscale PHATE Exploration of SARS-CoV-2 Data Reveals Multimodal Signatures of Disease Manik Kuchroo1∗, Jessie Huang2∗, Patrick Wong3∗, Jean-Christophe Grenier4, Dennis Shung5, Alexander Tong2, Carolina Lucas3, Jon Klein3, Daniel Burkhardt6, Scott Gigante7, Abhinav Godavarthi8, Benjamin Israelow3, Tianyang Mao3, Ji Eun Oh3, Julio Silva3, Takehiro Takahashi3, Camila D. Odio5, Arnau Casanovas-Massana9, John Fournier10, Yale IMPACT Team11, Shelli Farhadian10, Charles S. Dela Cruz12, Albert I. Ko9, F. Perry Wilson13, Julie Hussin4;14x, Guy Wolf15;16x, Akiko Iwasaki3;17x;y and Smita Krishnaswamy2;6x;y 1Department of Neuroscience, Yale University, New Haven, CT, 2Department of Computer Science, Yale University, New Haven, CT, 3Department of Immunobiology, Yale University, New Haven, CT, 4Montreal Heart Institute, Montréal, Québec, Canada, 5Department of Medicine, Yale University, New Haven, CT, 6Department of Genetics, Yale University, New Haven, CT, 7Computational Biology, Bioinformatics Program,Yale University, New Haven, CT, 8Department of Applied Mathematics, Yale University, New Haven, CT, 9Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, 10Department
[Show full text]
OBSERVATORIO DE LA CRISIS COVID-19 Secretaria De Investigación
OBSERVATORIO DE LA CRISIS COVID-19 Secretaria de Investigación. Recopilación de Prensa y sitios web de interés. BOLETIN Nº15 31 de julio al 14 de agosto de 2020 INDICE Análisis estratégicos Información de Latinoamérica Argentina y México producirán la vacuna de Aumento de contagios al interior del Ejército Oxford: costará u$s 4 y estará lista en el pri- preocupa en Bolivia....................................................................27 mer semestre de 2021 .................................................................5 ONU reclama ayuda internacional a la Ama- General Juan Martín Paleo: “Vivimos la crisis zonía por avance de COVID.........................................................27 sanitaria de manera muy intensa”...............................................6 Colombia, un mes más en cuarentena......................................28 ¿Podemos volver a infectarnos del corona- virus? Los expertos creen que es muy poco Ecuador Los grupos élite de las Fuerzas Ar- probable?......................................................................................9 madas, contra el covid-19................................ ..........................29 La OMS advierte de que “quizá no haya nun- ca” una cura contra la Covid-19.................................................12 Información de América del Norte y el Caribe La OMS advierte que los efectos del Covid La Casa Blanca alerta de una expansión «ex- durarán décadas.........................................................................14 traordinaria» del Covid-19 en EE.UU.............
[Show full text]
00:00 - Good Morning
00:00 - Good morning. 00:01 Welcome and thank you for joining us 00:03 for our Northern Light Health 00:04 Business to Business Zoom conference. 00:07 Today, our theme is Vaccine Hesitancy, 00:09 Myths, Misinformation, and What We Know Now. 00:14 The pandemic has been very dynamic. 00:16 We will provide you with the latest information, 00:19 recognizing that it is a continuously evolving situation. 00:24 We are now into our fifth month of vaccinating people. 00:27 While people of all ages may be hesitant 00:30 to receive a vaccination, 00:32 we are seeing a drop-off in demand 00:34 as vaccines have been made available 00:36 to everyone 16 and older. 00:39 We'll take a look at the current status 00:41 of COVID-19 and vaccinations. 00:44 And with this as a platform, we'll explore vaccine hesitancy 00:47 with our panel of special guests and experts. 00:51 I'm Dr. Ed Gilkey, Senior Physician Executive 00:54 at Northern Light Beacon Health. 00:56 I'll be your moderator for the next hour. 00:58 Our panelists today are Dr. Melissa Maginnis, 01:03 a virologist from the University of Maine, 01:07 Dr. Elizabeth Marnik, 01:09 an immunologist from Husson University, 01:13 Dr. Jim Jarvis, a physician leader and clinical leader 01:17 for mass vaccinations at Northern Light Health. 01:21 And our other special guests today are Remi Geohegan, 01:26 Tanisha Gilbert, and Emily McLaughlin.
[Show full text]
Letter from the American Association of Immunologists April 15, 2020 Page 2 of 3 Fox Jumped Over the Lazy Dog
The AMERICAN ASSOCIATION of IMMUNOLOGISTS President Jeremy M. Boss, Ph.D. April 15, 2020 Vice President The quick brown fox jumped over the lazy dog. The quick brown fox jumped over the Jenny P. Ting, Ph.D.lazy dog. ThePresident quick Donald brown J. fox Trump jumped over the lazy dog.The The Honorable quick brown Nancy Pelosifox jumped Past President over the lazyThe dog.White The House quick brown fox jumped over the Speaker lazy dog. The quick brown fox JoAnne L. Flynn, Ph.D.jumped ov1600er the Pennsylvania lazy dog. The Avenue, quick N.W. brown fox jumped U.S. over House the lazyof Representatives dog. The quick Secretary-Treasurerbrown foxWashington, jumped over D.C. the 20500 lazy dog. The quick brown Hfox-232, jumped The Capitol over the lazy dog. The Edith M. Lord, Ph.D.quick brown fox jumped over the lazy dog. The quick brownWashington, fox jumped D.C. 20515 over the lazy Councillors dog. The quickThe Honorable brown fox Mitch jumped McConnell over the lazy dog. The quick brown fox jumped over Gary A. Koretzky, M.D.,the lazyPh.D. dog.Majority The quick Leader brown fox jumped over the lazyThe dog. Honorable The quick Kevin brown McCarthy fox Mark M. Davis, Ph.D. Akiko Iwasaki, Ph.D.jumped overUnited the lazyStates dog. Senate The quick brown fox jumped Minority over the Leader lazy dog. The quick Stephen Jameson, Ph.D.brown foxS jumped-230, The over Capitol the lazy dog. The quick brown U.S.fox Housejumped of over Representatives the lazy dog.
[Show full text]
Download Program
Oral Program Sunday, October 1, 2017 11:00-13:00 Registration Room: Hotel Lobby North/Assembly Foyer Room South Ballroom 13:00-13:15 Opening Remarks, Editorial Organizers 13:15-14:15 Opening Keynote: Anthony S. Fauci, NIAID, USA Emerging and Re-Emerging Infectious Diseases: From AIDS to Zika [KEY1] 14:15-17:45 Session 1: Genomics & Evolution Session Chair: Akiko Iwasaki, Yale University 14:15-14:45 George Fu Gao, Chinese Academy of Sciences, China Enveloped virus entry: From Flu to Ebola [INV01] 14:45-15:00 [ST01] Functional Evolution of Zika Virus in the Americas N.D. Grubaugh*, C. Ontiveros, R. Agarwal, T. Rogers, N. Beutler, K. Gangavarapu, G. Oliveira, R. Robles- Sikisaka, D. Burton, K.G. Andersen The Scripps Research Institute, USA 15:00-15:15 [ST02] Characterization of a clade-defining Ebola virus glycoprotein mutant from the 2013-2016 epidemic W.E. Diehl1, D. Mu1, A.E. Lin3, M. Cabot2, K.G. Andersen4, J.H. Kuhn6, P. Sabeti3, B. Ganser-Pornillos2, J. White2, J. Luban*1 et al 1University of Massachusetts Medical School, USA, 2University of Virginia, USA, 3Harvard University, USA, 4The Scripps Research Institute, USA, 5University of Edinburgh, UK, 6NIAID, USA 15:15-15:45 Gustavo Palacios, USAMRIID Center for Genomic Sciences, USA Near real-time genomics applications in clinical virology and biosurveillance [INV02] 15:45-16:15 Refreshment Break Room: North Ballroom 16:15-16:45 Linfa Wang, Duke-NUS Medical School, Singapore Programme in emerging infectious diseases [INV03] 16:45-17:00 [ST03] Immune correlates of protection from a universal influenza vaccine during intra- and intersubtypic heterologous challenge with H1, H6, H7 and H10 influenza viruses J.C.
[Show full text]
HZS C2BRNE DIARY – January 2021
1 HZS C2BRNE DIARY – January 2021 www.cbrne-terrorism-newsletter.com 2 HZS C2BRNE DIARY – January 2021 HZS C2BRNE DIARY– 2021© January 2021 Website: www.cbrne-terrorism-newsletter.com Editor-in-Chief BrigGEN (ret.) Ioannis Galatas MD, MSc, MC (Army) PhD cand Consultant in Allergy & Clinical Immunology Medical/Hospital CBRNE Planner & Instructor Senior Asymmetric Threats Analyst Manager, CBRN Knowledge Center @ International CBRNE Institute (BE) Senior CBRN Consultant @ HotZone Solutions Group (NL) Athens, Greece Contact e-mail: [email protected] Editorial Team ⚫ Bellanca Giada, MD, MSc (Italy) ⚫ Hopmeier Michael, BSc/MSc MechEngin (USA) ⚫ Kiourktsoglou George, BSc, Dipl, MSc, MBA, PhD (UK) ⚫ Photiou Steve, MD, MSc EmDisaster (Italy) ⚫ Tarlow Peter, PhD Sociol (USA) A publication of HotZone Solutions Group Prinsessegracht 6, 2514 AN, The Hague, The Netherlands T: +31 70 262 97 04, F: +31 (0) 87 784 68 26 E-mail: [email protected] DISCLAIMER: The HZS C2BRNE DIARY® (former CBRNE-Terrorism Newsletter), is a free online publication for the fellow civilian/military CBRNE First Responders worldwide. The Diary is a collection of papers/articles related to the stated thematology. Relevant sources/authors are included and all info provided herein is from open Internet sources. Opinions and comments from the Editor, the Editorial Team or the authors publishing in the Diary do not necessarily represent those of the HotZone Solutions Group (NL) or the International CBRNE Institute (BE). www.cbrne-terrorism-newsletter.com 3 HZS C2BRNE DIARY – January 2021 www.cbrne-terrorism-newsletter.com 4 HZS C2BRNE DIARY – January 2021 www.cbrne-terrorism-newsletter.com 5 HZS C2BRNE DIARY – January 2021 Editorial Brig Gen (ret.) Ioannis Galatas, MD, MSc, MC (Army) Editor-in-Chief HZS C2BRNE Diary Dear Colleagues, New Year, Blank Page? effects and duration of effectiveness of vaccination.
[Show full text]
Croi 2021 Program Committee
General Information CONTENTS WELCOME . 2 General Information General Information OVERVIEW . 2 CONTINUING MEDICAL EDUCATION . 3 CONFERENCE SUPPORT . 4 VIRTUAL PLATFORM . 5 ON-DEMAND CONTENT AND WEBCASTS . 5 CONFERENCE SCHEDULE AT A GLANCE . 6 PRECONFERENCE SESSIONS . 9 LIVE PLENARY, ORAL, AND INTERACTIVE SESSIONS, AND ON-DEMAND SYMPOSIA BY DAY . 11 SCIENCE SPOTLIGHTS™ . 47 SCIENCE SPOTLIGHT™ SESSIONS BY CATEGORY . 109 CROI FOUNDATION . 112 IAS–USA . 112 CROI 2021 PROGRAM COMMITTEE . 113 Scientific Program Committee . 113 Community Liaison Subcommittee . 113 Former Members . 113 EXTERNAL REVIEWERS . .114 SCHOLARSHIP AWARDEES . 114 AFFILIATED OR PROXIMATE ACTIVITIES . 114 EMBARGO POLICIES AND SOCIAL MEDIA . 115 CONFERENCE ETIQUETTE . 115 ABSTRACT PROCESS Scientific Categories . 116 Abstract Content . 117 Presenter Responsibilities . 117 Abstract Review Process . 117 Statistics for Abstracts . 117 Abstracts Related to SARS-CoV-2 and Special Study Populations . 117. INDEX OF SPECIAL STUDY POPULATIONS . 118 INDEX OF PRESENTING AUTHORS . .122 . Version 9 .0 | Last Update on March 8, 2021 Printed in the United States of America . © Copyright 2021 CROI Foundation/IAS–USA . All rights reserved . ISBN #978-1-7320053-4-1 vCROI 2021 1 General Information WELCOME TO vCROI 2021 Welcome to vCROI 2021! The COVID-19 pandemic has changed the world for all of us in so many ways . Over the past year, we have had to put some of our HIV research on hold, learned to do our research in different ways using different tools, to communicate with each other in virtual formats, and to apply the many lessons in HIV research, care, and community advocacy to addressing the COVID-19 pandemic . Scientists and community stakeholders who have long been engaged in the endeavor to end the epidemic of HIV have pivoted to support and inform the unprecedented progress made in battle against SARS-CoV-2 .
[Show full text]
What the Lightning-Fast Quest for Covid Vaccines Means
Feature MICHAEL CLEVENGER/GETTY The first US shipments of the joint Pfizer–BioNTech COVID-19 vaccine were ready by mid-December. making vaccines, such as by using messenger RNA (mRNA), have been validated by the WHAT THE LIGHTNING-FAST COVID-19 response, he adds. “It has shown that the development process can be accelerated QUEST FOR COVID VACCINES substantially without compromising on safety.” The world was able to develop COVID-19 MEANS FOR OTHER DISEASES vaccines so quickly because of years of pre- vious research on related viruses and faster The speedy approach used to tackle SARS-CoV-2 could ways to manufacture vaccines, enormous funding that allowed firms to run multiple change the future of vaccine science. By Philip Ball trials in parallel, and regulators moving more quickly than normal. Some of those factors might translate to other vaccine efforts, par- ticularly speedier manufacturing platforms. But there’s no guarantee. To repeat such hen scientists began seeking That speed of advance “challenges our rapid success will require similar massive fund- a vaccine for the SARS-CoV-2 whole paradigm of what is possible in vaccine ing for development, which is likely to come coronavirus in early 2020, they development”, says Natalie Dean, a biostatisti- only if there is a comparable sense of social were careful not to promise cian at the University of Florida in Gainesville. and political urgency. It will depend, too, on quick success. The fastest It’s tempting to hope that other vaccines might the nature of the pathogen. With SARS-CoV-2, any vaccine had previously now be made on a comparable timescale.
[Show full text]